Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 2
1975 9
1976 9
1977 16
1978 21
1979 39
1980 68
1981 31
1982 46
1983 55
1984 75
1985 83
1986 80
1987 74
1988 93
1989 101
1990 123
1991 104
1992 133
1993 135
1994 153
1995 138
1996 165
1997 169
1998 202
1999 187
2000 235
2001 246
2002 260
2003 306
2004 350
2005 387
2006 452
2007 473
2008 568
2009 538
2010 645
2011 696
2012 804
2013 829
2014 858
2015 947
2016 940
2017 963
2018 1080
2019 1087
2020 1222
2021 1339
2022 1276
2023 1284
2024 1009

Text availability

Article attribute

Article type

Publication date

Search Results

18,952 results

Results by year

Filters applied: . Clear all
Page 1
[Hormone and breast cancer].
Gompel A. Gompel A. Presse Med. 2019 Oct;48(10):1085-1091. doi: 10.1016/j.lpm.2019.09.021. Epub 2019 Oct 26. Presse Med. 2019. PMID: 31662219 Review. French.
Pregnancy decreases the risk if at a young age but after 25 years may increase the risk. Combined menopause hormone treatment is associated to a greater risk than estrogens alone. Breast cancer associated with hormone treatment is estradiol receptor …
Pregnancy decreases the risk if at a young age but after 25 years may increase the risk. Combined menopause hormone treatment is asso …
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Burstein HJ, et al. J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452337
RECOMMENDATIONS: The Panel recommends that women with node-positive breast cancer receive extended therapy, including an AI, for up to a total of 10 years of adjuvant endocrine treatment. ...Additional information can be found at www.asco.org/breast- …
RECOMMENDATIONS: The Panel recommends that women with node-positive breast cancer receive extended therapy, including a …
Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.
Matthews SB, Sartorius CA. Matthews SB, et al. Horm Cancer. 2017 Feb;8(1):4-15. doi: 10.1007/s12672-016-0275-0. Epub 2016 Oct 28. Horm Cancer. 2017. PMID: 27796944 Free PMC article. Review.
These new models capture the large degree of heterogeneity between patients and within tumors and promise to advance our understanding of steroid hormone receptor positive breast cancer and endocrine resistance. Unfortunately, steroid hormone …
These new models capture the large degree of heterogeneity between patients and within tumors and promise to advance our understanding of st …
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Robertson JFR, et al. Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29. Lancet. 2016. PMID: 27908454 Clinical Trial.
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-fr …
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic …
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Andrahennadi S, Sami A, Manna M, Pauls M, Ahmed S. Andrahennadi S, et al. Curr Oncol. 2021 May 11;28(3):1803-1822. doi: 10.3390/curroncol28030168. Curr Oncol. 2021. PMID: 34064867 Free PMC article. Review.
Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. ...They can also be used for primary prevention in women with a high risk of breast cancer. Prelimin …
Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent …
Progesterone and Breast Cancer.
Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Trabert B, et al. Endocr Rev. 2020 Apr 1;41(2):320-44. doi: 10.1210/endrev/bnz001. Endocr Rev. 2020. PMID: 31512725 Free PMC article. Review.
Synthetic progestogens (progestins) have been linked to increased breast cancer risk; however, the role of endogenous progesterone in breast physiology and carcinogenesis is less clearly defined. ...Given conflicting data related to the potential role of prog …
Synthetic progestogens (progestins) have been linked to increased breast cancer risk; however, the role of endogenous progeste …
Sequencing systemic therapy in hormone-receptor positive metastatic breast cancer: a modern paradigm.
Haddad SA, Dizon DS, Graff SL. Haddad SA, et al. Chin Clin Oncol. 2023 Aug;12(4):42. doi: 10.21037/cco-23-22. Epub 2023 Aug 10. Chin Clin Oncol. 2023. PMID: 37574571 Free article. Review.
Deaths from metastatic breast cancer continue to be a leading cause of global cancer mortality among women. The pace of advances in the treatment of hormone-receptor positive metastatic breast cancer (HR+ MBC) has introduced …
Deaths from metastatic breast cancer continue to be a leading cause of global cancer mortality among women. The pace of …
Hormone receptor-positive breast cancer and black race: does sex matter?
Eskander MF, Li Y, Bhattacharyya O, Tsung A, Oppong BA, Hamad A, Gatti-Mays M, Obeng-Gyasi S. Eskander MF, et al. Breast Cancer Res Treat. 2021 Nov;190(1):111-119. doi: 10.1007/s10549-021-06359-5. Epub 2021 Aug 12. Breast Cancer Res Treat. 2021. PMID: 34383180 Free PMC article.
The objective of this study is to examine differences in presentation, treatment, and mortality between Black MBC and FBC. METHODS: The National Cancer Database was queried for all Black MBC and FBC patients, ages 18-90, with hormone receptor-positive …
The objective of this study is to examine differences in presentation, treatment, and mortality between Black MBC and FBC. METHODS: The Nati …
The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer.
Yuan J, Yang L, Li Z, Zhang H, Wang Q, Huang J, Wang B, Mohan CD, Sethi G, Wang G. Yuan J, et al. Front Endocrinol (Lausanne). 2023 Oct 13;14:1261283. doi: 10.3389/fendo.2023.1261283. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37900137 Free PMC article. Review.
Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resistance to endocrine therapy is a major health concern among hormone-positive breast cancer patients. ...In sum, …
Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resi …
18,952 results
You have reached the last available page of results. Please see the User Guide for more information.